Volume 26, Issue 5 (8-2019)
RJMS 2019, 26(5): 79-86 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Amiri Kojuri N, Esmaeili A H. Factors evaluation of oxidant–antioxidant malondialdehyde, plasma total antioxidant and vitamin C in type 1 diabetes patients compared with healthy people. RJMS 2019; 26 (5) :79-86
URL: http://rjms.iums.ac.ir/article-1-5533-en.html
URL: http://rjms.iums.ac.ir/article-1-5533-en.html
, nasim.amiri20@gmail.com
Abstract: (3352 Views)
Background: One of the most important prevalent and chronic diseases is diabetes. The conditions of oxidative stress and missing equilibrium of antioxidants have an important and main role in emerging and development of this disease. Evaluating the factors of oxidant – antioxidant Malondialdehyde, plasma total antioxidant and Vitamin C in type 1 diabetes patients is the main purpose of the present study.
Methods: In the present case – control study, 30 patients suffering from type 1 diabetes were compared with 30 healthy persons. The capacity of plasma total antioxidant was measured with FRAP method. Malondialdehyde was measured as final production of lipids peroxidation based on Hadley and Draper method and evaluation of vitamin C level using Roe and Queter method. Statistical analysis was done using T statistical test and SPSS soft ware. P <0.05 was considered as significant level.
Results: The mean and standard deviation of plasma total antioxidant in persons with case 35.11±8.04 and in persons with control 36.19±2.3 µmol/L that statistically was significant (p= 0.000). The amount of MAD as a factor lipids peroxidation in persons with case 16.52±1.14 and in persons with control 15.42±2.34 µmol/L (p= 0.056). Vitamin C level in persons with case and control 7.43±0.67 and 8.76±2.86 mg/dl (p= 0.000).
Conclusion: In the present research, the level of plasma total antioxidant and vitamin C in patients suffering diabetes has been significantly less than control group. Malondialdehyde level showed a significant increase in the case group. Therefore, it is recommended to consume and use natural antioxidants much more in order to reduce damages originate from free radicals.
Methods: In the present case – control study, 30 patients suffering from type 1 diabetes were compared with 30 healthy persons. The capacity of plasma total antioxidant was measured with FRAP method. Malondialdehyde was measured as final production of lipids peroxidation based on Hadley and Draper method and evaluation of vitamin C level using Roe and Queter method. Statistical analysis was done using T statistical test and SPSS soft ware. P <0.05 was considered as significant level.
Results: The mean and standard deviation of plasma total antioxidant in persons with case 35.11±8.04 and in persons with control 36.19±2.3 µmol/L that statistically was significant (p= 0.000). The amount of MAD as a factor lipids peroxidation in persons with case 16.52±1.14 and in persons with control 15.42±2.34 µmol/L (p= 0.056). Vitamin C level in persons with case and control 7.43±0.67 and 8.76±2.86 mg/dl (p= 0.000).
Conclusion: In the present research, the level of plasma total antioxidant and vitamin C in patients suffering diabetes has been significantly less than control group. Malondialdehyde level showed a significant increase in the case group. Therefore, it is recommended to consume and use natural antioxidants much more in order to reduce damages originate from free radicals.
Type of Study: Research |
Subject:
Clinical Biochemistry
References
2. 1. Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature; 2010. 464: 1293–1300.
3. 2. Gianani R, Campbell-Thompson M, Sarkar SA, Wasserfall C, Pugliese A, Solis JM, et al. Dimorphic histopathology of long-standing childhood-onset diabetes. Diabetologia; 2010. 53: 690–8.
4. 3. Chikezie PC, Ojiako OA, Agomuo C, Ogbuji AC. Oxidative stress in diabetes mellitus. Integr Obesity. Diabetes; 2015. 1(3): 71-79.
5. 4. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res; 2010.
6. 107: 1058-70.
7. 5. Jane LCh, MSue K, Lori MBL, Anne LP. Type 1 Diabetes through the Life Span: A Position Statement of the Span: American Diabetes Association. Diabetes Care; 2014. 37: 2034–54.
8. 6. Sacks DB, Path FRC. Diabetes, Tiets Fundamentals of Clinical chemistry and Molecular Diagnostics. Karimi S, 7nd ed, Tehran, Arjmand, 2015; pp: 499.
9. 7. Dayem AA, Choi HY, Kim JH, Cho SG. Role of oxidative stress in stem, cancer, and cancer stem cells. Cancers (Basel); 2010. 2(2):859-84.
10. 8. Ojiako AO, Chikezie PC, Ogbuji CA. Renal and hepatic antioxidant status of
11. hyperglycemic rats treated with single and combinatorial herbal formulations. Pharmacogn Commun; 2015. 5: 148-59.
12. 9. Bajaj S, Khan A. Antioxidants and diabetes. Indian J Endocrinol Metabol; 2012. 16: 267-71.
13. 10. Styskal J, Van Remmen H, Richardson A, Salmon AB. Oxidative stress and diabetes: what can we learn about insulin resistance from antioxidant mutant mouse models? Free Radic Biol Med; 2012. 52: 46-58.
14. 11. Sosa V, Moline T, Somoza R, Paciucci R, Kondoh H, LLeonart ME. Oxidative stress and cancer: an overview. Ageing Res Rev; 2013.12(1):376- 90.
15. 12. Etsuo N. Antioxidant capacity: Which capacity and how to assess it? J Berry Res; 2011. 10(32): 169–76.
16. 13. Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of antioxidant power: the FRAP assay. Anal Biochem; 1996. 239 (1): 70-76.
17. 14. Benzie IFF, Strain JJ. Ferric reducing antioxidant power assay: direct measure of total antioxidant activity of biological fluids and modified version for simultaneous measurement of
18. total antioxidant power and ascorbic acid concentration. Methods Enzymol; 1999. 299: 15-27.
19. 15. Draper HH, Hadley M. Malondialdehyde determination as an index of lipid peroxidation. Methods Enzymol; 1990. 186: 421–31.
20. 16. Firoozrai M, Soloukizadeh N, Danesh Doust L,Ghafari M. Levels of ascorbic acid (Vitamin C) in plasma and mononuclear leukocytes of patients with typel II diabetes mellitus. Razi J Med Sci; 2000. 7(21): 207-13. [Persian]
21. 17. Thavatchai P, Atip L, Natchai P, Anchaleekorn S. Antioxidant Status and Lipid Peroxidation End Products in Patients of Type 1 Diabetes Mellitus. J Med Assoc Thai; 2006. 89(5): 141- 6.
22. 18. Dana M. The Role of Oxidative Stress in
23. Diabetic Complications. Cell Biochem Biophys; 2005. 43:289-330.
24. 19. Munnia A, Bonassi S, Verna A, Quaglia R, Pelucco D, Ceppi M, et al. Bronchial malondialdehyde DNA adducts, tobacco smoking, and lung cancer. Free Radic Biol Med; 2006. 41(9): 1499-505.
25. 20. Merendino RA, Salvo F, Saija A, Di Pasquale G, Tomaino A, Minciullo PL, et al. Malondialdehyde in benign prostate hypertrophy: a useful marker? Mediators Inflamm; 2003. 12(2): 127-8.
26. 21. Castro Correia C, Luz Maiac BFM, Norbertoc S, Cristina CS, Barrosoc F, Carvalho A. Can Antioxidative Status Be Involved in Type 1 Diabetes? J Clin Med Res; 2017.9(12): 998-1001.
27. 22. Varvarovska J, Racek J, Stozicky F, Soucek J, Trefil L, Pomahacova R. Parameters of oxidative stress in children with Type 1 diabetes mellitus and their relatives. J Diabetes Complicat; 2003.17(1):7-10.
28. 23. Dalgic B, Sonmez N, Biberoglu G, Hasanoglu A, Erbas D. Evaluation of oxidant stress in Wilson's disease and non-Wilsonian chronic liver disease in childhood. Tur J Gastroenter; 2005. 16(1): 7-11.
29. 24. Davis KA, Lee WYL, Labbe RF. Energy dependent transport of ascorbic acid into lymphocytes. Fed Proc; 1983. 42: 2011-18.
30. 25. Chen MS , Hutchinson ML, Pecoraro RE. Hyperglyccemia – induced intracellular depletion of ascorbic acid in Human mononuclear leukocytes. Diabetes; 1983. 32(11): 1078-81.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
